

MR# 316063

December 22, 2008

This Report has been sanitized of Confidential Business Information

**DELIVERY BY USPS-certified
CONFIRMATION OF RECEIPT REQUESTED**



Document Control Office (7407M)
U.S. Environmental Protection Agency
Attn: TSCA Section 8(e) Coordinator
Office of Pollution Prevention and Toxics
1200 Pennsylvania Avenue, NW
Washington, DC 20460-0001

RECEIVED
EPA/PT/CRIC
2008 DEC 23 AM 8:29
09 Jan 2

SUBJECT: TSCA 8(e) SUBMISSION

Dear Sir or Madam:

(") is submitting certain data, which we believe to be reportable under TSCA 8(e). The information concerns (), an experimental sulfone insecticide compound. is identified by IUPAC as:


The CAS number for this compound is not yet assigned.

has not imported for R&D on behalf of ("), but plans to do so in the future.

This will be the third report of adverse effects observed in rats given in an acute oral toxicity study being submitted to EPA. The first acute oral toxicity rat report (Document Control Number) was submitted to your agency on (Received EPA); the second was just submitted on the of and has not been assigned a Document Control Number. Additionally, on the of r, we submitted report of adverse affects in a micronucleus study for which we are awaiting notification of the Document Control Number.

An outline of the study follows:

Company Sanitized



3rd Acute Oral Toxicity Study of () in Rats

Study conducted by: (Study No.)

Animals: BriHan: WIST@Jcl rats, 8 weeks old, 6 animals/sex/dose
Pre-dose fasting: approximately 20 hours prior to administration of the test substance
Dose: 300 mg/kg
Dose volume: 10 mL/kg
Administration: oral
Vehicle: Corn oil
Body weight: Males: 221-233 g; females: 157-164 g; at the start of the study
Observation: The animals were monitored for clinical signs at 10 minutes, 30 minutes, and 4 hours post-administration of the test substance; thereafter, once daily for 7 days

Examinations were: clinical signs


The following adverse health effects were noted during the course of this study, which believes to be reportable under TSCA 8(e):

No males died in this study in which animals were given a single dose of 300 mg/kg of the test substance. Two of the six females in the 300 mg/kg group died. Some of females and males displayed muscular rigidity, and one female displayed clonic convulsion. No other clinical signs were observed in the other animals in this study.

Substantiation of CBI Claims

We wish to substantiate 's claims that certain information in this letter be treated as Confidential Business Information ('CBI'). All information deleted from the sanitized version of this letter (copy attached) should be treated as CBI. In substantiation of this CBI claim wishes to protect its confidential business plan for the commercial development of this compound. Disclosure of this information would harm s efforts to commercialize this compound. Please refer to the attached a letter of to Mr. Edward Gross regarding substantiation of CBI claims.

If there are any questions on this submission please feel free to contact me at (-).



Sincerely,

Director

Encl.

cc: